How Have the Numbers Shaped Up for Hancock Jaffe Laboratories (NASDAQ:HJLI)

0
151

Earnings results for Hancock Jaffe Laboratories (NASDAQ:HJLI)

Hancock Jaffe Laboratories, Inc. is estimated to report earnings on 08/31/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.13.

Hancock Jaffe Laboratories last released its quarterly earnings results on June 8th, 2020. The reported ($0.06) EPS for the quarter. Hancock Jaffe Laboratories has generated $0.00 earnings per share over the last year. Hancock Jaffe Laboratories has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 31st, 2020 based off prior year’s report dates.

Analyst Opinion on Hancock Jaffe Laboratories (NASDAQ:HJLI)

1 Wall Street analysts have issued ratings and price targets for Hancock Jaffe Laboratories in the last 12 months. Their average twelve-month price target is $3.00, predicting that the stock has a possible upside of 574.31%. The high price target for HJLI is $3.00 and the low price target for HJLI is $3.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

Hancock Jaffe Laboratories has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $3.00, Hancock Jaffe Laboratories has a forecasted upside of 574.3% from its current price of $0.44. Hancock Jaffe Laboratories has received no research coverage in the past 90 days.

Dividend Strength: Hancock Jaffe Laboratories (NASDAQ:HJLI)

Hancock Jaffe Laboratories does not currently pay a dividend. Hancock Jaffe Laboratories does not have a long track record of dividend growth.

Insiders buying/selling: Hancock Jaffe Laboratories (NASDAQ:HJLI)

In the past three months, Hancock Jaffe Laboratories insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,600.00 in company stock. Only 3.90% of the stock of Hancock Jaffe Laboratories is held by insiders. Only 0.33% of the stock of Hancock Jaffe Laboratories is held by institutions.

Earnings and Valuation of Hancock Jaffe Laboratories (NASDAQ:HJLI

Hancock Jaffe Laboratories has a P/B Ratio of 44.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here